These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 8549345)

  • 1. Pharmacokinetics of ofloxacin--measurement of drug concentration in saliva of patients with impaired renal function.
    Fujita K; Matsuoka N; Takenaka I; Hiraishi K; Yokota T; Asahi T; Tatara K; Yuasa M; Kaifu Y; Kawano A
    Drugs; 1995; 49 Suppl 2():312-3. PubMed ID: 8549345
    [No Abstract]   [Full Text] [Related]  

  • 2. [Ten-year experience with the use of ofloxacin (Tarivid*). New treatment regimens].
    Navashin SM; Navashin PS; Smirnova LB
    Antibiot Khimioter; 1996; 41(9):99-103. PubMed ID: 9005800
    [No Abstract]   [Full Text] [Related]  

  • 3. [The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
    Budanov SV; Vasil'ev AN; Smirnova LB
    Antibiot Khimioter; 2001; 46(7):38-46. PubMed ID: 11697244
    [No Abstract]   [Full Text] [Related]  

  • 4. The fluoroquinolones after ciprofloxacin and ofloxacin.
    Hooper DC
    Curr Clin Top Infect Dis; 2000; 20():63-91. PubMed ID: 10943519
    [No Abstract]   [Full Text] [Related]  

  • 5. A randomised controlled trial of ofloxacin 200 mg 4 times daily or twice daily vs ciprofloxacin 500 mg twice daily in elderly nursing home patients with complicated UTI.
    McCue JD; Gaziano P; Orders D
    Drugs; 1995; 49 Suppl 2():368-73. PubMed ID: 8549365
    [No Abstract]   [Full Text] [Related]  

  • 6. Ofloxacin concentrations in serum, saliva and pleural effusion of patients with pulmonary tuberculosis and lung cancer.
    Miya T; Hamakubo S; Goya T; Hanaoka T; Hosaka K
    Jpn J Antibiot; 1995 Jul; 48(7):960-4. PubMed ID: 7563589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics and distribution of ofloxacin into the lower respiratory tract.
    Walstad RA; Vilsvik JS; Thurmann-Nielsen E; Rolstad T
    Drugs; 1995; 49 Suppl 2():344-5. PubMed ID: 8549356
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effectiveness of levofloxacin (Tavanik, "Aventis Pharma") in the treatment of complicated infections of the urogenital organs].
    Derevianko II; Lavrinova LN; Kudriashova EE
    Urologiia; 2003; (1):31-4. PubMed ID: 12621964
    [No Abstract]   [Full Text] [Related]  

  • 9. Respiratory tract penetration of quinolone antimicrobials: a case in study.
    Ritrovato CA; Deeter RG
    Pharmacotherapy; 1991; 11(1):38-49. PubMed ID: 2020610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The importance of fluoroquinolones in treating pneumonia in the elderly].
    Belousov IuB; Efremenkova OV; Sokolov AV; Tishenkova IF
    Antibiot Khimioter; 1999; 44(12):23-6. PubMed ID: 10687030
    [No Abstract]   [Full Text] [Related]  

  • 11. Kinetics of absorption and elimination of ofloxacin in humans after oral and rectal administrations.
    Eboka CJ; Okor RS; Akerele JO; Aigbavboa SO
    J Clin Pharm Ther; 1997 Jun; 22(3):217-20. PubMed ID: 9447477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective monitoring of concentrations of ofloxacin in saliva of patients with chronic respiratory tract infections.
    Koizumi F; Ohnishi A; Takemura H; Okubo S; Kagami T; Tanaka T
    Antimicrob Agents Chemother; 1994 May; 38(5):1140-3. PubMed ID: 8067752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections.
    Martin SJ; Jung R; Garvin CG
    Drug Saf; 2001; 24(3):199-222. PubMed ID: 11347723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo activity of ciprofloxacin, ofloxacin, norfloxacin and pipemidic acid against Escherichia coli infections in mice.
    Obana Y; Nishino T
    Drugs Exp Clin Res; 1989; 15(2):53-8. PubMed ID: 2661182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Use of antibiotics in chronic bronchitis].
    Guseĭnov KhIu
    Probl Tuberk; 2000; (1):23-4. PubMed ID: 10750424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of lomefloxacin and ofloxacin in complex therapy of infections in patients with burns].
    Krutikov MG; Alekseev AA; Bobrovnikov AE; Grishina IA; Elagina LV; Izotova GN; Iakovlev VP
    Antibiot Khimioter; 1998; 43(10):27-31. PubMed ID: 9825107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single dose UTI prophylaxis in transurethral surgery. Oral ofloxacin vs parenteral cefotaxime.
    Madsen PO; Malek GH; Kahn JB
    Drugs; 1995; 49 Suppl 2():480-2. PubMed ID: 8549408
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetics of ofloxacin in drug-resistant tuberculosis.
    Chulavatnatol S; Chindavijak B; Chierakul N; Klomsawat D
    J Med Assoc Thai; 2003 Aug; 86(8):781-8. PubMed ID: 12948278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levofloxacin: penetration into sputum and once-daily treatment of respiratory tract infections.
    Nakamori Y; Miyashita Y; Nakatani I; Nakata K
    Drugs; 1995; 49 Suppl 2():418-9. PubMed ID: 8549384
    [No Abstract]   [Full Text] [Related]  

  • 20. [Pharmacokinetics and dose adaptation of ofloxacine, pefloxacine and ciprofloxacine during haemodialysis and continuous ambulatory peritoneal dialysis].
    Daniel JP; Moulin B; Christmann D
    Ann Pharm Fr; 2004 May; 62(3):177-85. PubMed ID: 15243351
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.